AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT			1. CONTRACT ID CODE		PAGE OI	F PAGES
2, AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUISITION/PURC	HASE REQ. NO.	5. PROJEC	1 1 TNO. (If appl.	icable)
Amendment Two (2)	08/14/2015					ŕ
6. ISSUED BY CODE		7. ADMINISTERED BY (If other than Item 6)	CODE		
National Cancer Institute Office of Acquisitions, TSB Riverside Five, Suite 400 8490 Progress Drive, Room 4036 Frederick, MD 21701-4998						
8. NAME AND ADDRESS OF CONTRACTOR (No., street, co	ounty, State and ZIP Code)		(X) 9A. AMENDMEN	T OF SOLICE	TATION	
All potential offerors			NO. RFP N02CC 9B. DATED (SEE 07/30/2015 10A. MODIFICAT 10B. DATED (SE	TION OF CON		ER NO.
2005	OIL ITY CODE					
	CILITY CODE ONLY APPLIES TO	AMENDMENTS OF S				
The above numbered solicitation is amended as set fort			····			
or (c) By separate letter or telegram which includes a reference PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PR amendment your desire to change an offer already submitted and this amendment, and is received prior to the opening hou 12. ACCOUNTING AND APPROPRIATION DATA (If required 13. THIS ITEM O	IOR TO THE HOUR AND DA , such change may be made ur and date specified.	ATE SPECIFIED MAY RESU by telegram or letter, provid	ILT IN REJECTION OF \ ed each telegram or lette	OUR OFFER r makes refere	l. If by virtue of	f this
	THE CONTRACT/OR					
CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURS IN ITEM 10A.	SUANT TO: (Specify authorit	y) THE CHANGES SET FOR	RTH IN ITEM 14 ARE MA	ADE IN THE C	CONTRACT OF	₹DER NO.
B. THE ABOVE NUMBERED CONTRACT/O date, etc.) SET FORTH IN ITEM 14, PURS	SUANT TO THE AUTHORIT	Y OF FAR 43.103(b).	IVE CHANGES (such as	changes in pa	aying office, ap	propriation
C. THIS SUPPLEMENTAL AGREEMENT IS D. OTHER (Specify type of modification and		IT TO AUTHORITY OF:				
Responses to Questions Receiv	• •					
<u></u>	s required to sign this o	document and return	1 copie	s to the iss	uing office.	
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Orga	anized by UCF section headii	ngs, including solicitation/cor	ntract subject matter whe	re feasible.)		
The purpose of this modification is to provid Amendment also adds three (3) administration .			/7/15, 8/11/15 an	d 8/12/15.	. This	
Except as provided herein, all terms and conditions of the doc	cument referenced in Item 9A					
15A. NAME AND TITLE OF SIGNER (Type or print)		Mandie S. White, C		,	orint)	
15B. CONTRACTOR/OFFEROR	15C. DATE SIGNED	16B. UNITED STATES OF	MERICA White		16C. DAT	E SIGNED
(Signature of person authorized to sign)		7 00 00 - 10	e of Contracting Officer)	·	- <i>U/17</i>	//3

RFQ Number: N02CO54417-02, Total 100% Small Business Set-Aside

Amendment No. Two (2)

National Institutes of Health (NIH), National Cancer Institute (NCI)

Office of Acquisitions (OA), Treatment and Support Branch (TSB)

Date of Issuance: August 14, 2015

The above numbered Request for Quotation (RFQ) is amended as set forth below. The hour and date specified for receipt of responses remains <u>unchanged</u>.

This Amendment #2 provides responses to questions received on 8/7/15, 8/11/15 and 8/12/15 as stated below. This Amendment also adds three (3) administrative actions to the RFQ package.

Inquiry 1 -

Question 1: Does [the NCI] RFQ eliminate the Leidos operating CPTAC network?

Response 1: CPTAC is transitioning from Phase II to Phase III. Some aspects of the program are changing and many of the grants, contracts and subcontracts will undergo recompetition. The NCI RFQ does not eliminate the Leidos subcontract(s). The NCI RFQ seeks to collect additional tissue types beyond breast, colon and ovary.

Inquiry 2 -

Question 1: Do you consider any inclusion of pediatric AML?

Response 1: We will NOT include pediatric AML cases.

Inquiry 3 -

Question 1: Is the no authorship clause negotiable? [Our organization] is used to a model where the TSS's are actively involved with the disease focused working groups and are contributing authors.

Response 1: Yes, this is negotiable.

Question 2: The amount of tissue and DNA from blood is twice that was required for TCGA. Are these the absolute amounts or can smaller amounts be sent?

Response 2: The amounts are larger because proteomic assays require more tissue. Until proteomic technologies are demonstrated to use less sample, the stated amounts are required.

Question 3: [Our organization] has a number of retrospective cases, can these be sent?

Response 3: At this time, CPTAC is seeking only prospective cases.

Administrative Actions

1. Provide your organization's Data Universal Number System (DUNS). If you do not have a DUNS, please see the following link for more information http://fedgov.dnb.com/webform. Your

- organization must have a DUNS in order to register in the System for Award Management at https://www.sam.gov .
- 2. Verify registration in the System for Award Management at https://www.sam.gov. If your company is not registered, please do so as soon as possible.
- 3. Complete and provide a copy of representation and certifications at http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/52 212 3 508.pdf .

END OF AMENDMENT #2.